Loading...
•
Mar 31, 2025
Axsome Q1 2025 Earnings Report
Axsome reported Q1 2025 results with strong revenue growth driven by AUVELITY, but posted a net loss due to high SG&A and R&D investments.
Key Takeaways
Axsome Therapeutics grew revenue significantly in Q1 2025, led by AUVELITY sales, but continued to report net losses amid ongoing R&D and commercialization efforts.
Revenue by Segment
Forward Guidance
Axsome believes current cash levels are sufficient to reach cash flow positivity, with multiple regulatory submissions and product launches planned in 2025.
Positive Outlook
- SYMBRAVO commercial launch on track for June 2025
- AXS-14 NDA for fibromyalgia submitted; FDA decision on acceptance expected in Q2
- sNDA for AXS-05 in Alzheimer’s agitation planned for Q3 2025
- NDA for AXS-12 in narcolepsy expected in 2H 2025
- Positive Phase 3 results reported for multiple solriamfetol trials
Challenges Ahead
- Net loss continued due to high operating expenses
- Cash position declined slightly from previous quarter
- SUNOSI prescriptions down 5% QoQ
- SG&A expenses increased significantly due to pre-launch and marketing costs
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...